AVCNF (Avicanna) Current Deferred Revenue : $0.29 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Avicanna Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Avicanna's current deferred revenue for the quarter that ended in Dec. 2024 was $0.29 Mil.

Avicanna Current Deferred Revenue Historical Data

The historical data trend for Avicanna's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna Current Deferred Revenue Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Deferred Revenue

Get a 7-Day Free Trial

0.31

0.29

Avicanna Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Current Deferred Revenue	Get a 7-Day Free Trial															0.31	-	-	0.11	0.29

Avicanna Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Avicanna's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Avicanna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (OTCPK:AVCNF) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

0NN:Germany AVCN:Canada

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.